Michael Mina is an Epidemiologist, Immunologist and Physician, who is now the Chief Science Officer of eMed, a telehealth company. Through most of the pandemic, Dr. Mina was a professor in the Center for Communicable Disease Dynamics at the Harvard School of Public Health and an associate medical director and faculty member at Brigham and Women’s Hospital, Harvard Medical School. Read more
Dr. Mina has been at the forefront of the COVID pandemic, both in the development of new research, particularly surrounding testing and immunity based surveillance in this pandemic, and serving as an advisor for state, federal and international governments. Dr. Mina has been engaged with advising and developing testing protocols with both US administrations and most recently, he has been helping to build a strategic roadmap for the White House for addressing the next phases of the pandemic, alongside a leading group of public health experts.
Dr. Mina began his academics in engineering and public health at Dartmouth College, and completed his MD and PhD at Emory University, working on the intersection of influenza vaccine immunology, bacterial infections and mathematical models. Dr. Mina did his pathology training at Brigham and Women’s Hospital and Harvard Medical School. His post doctoral research was Princeton University, in mathematical modeling of infectious diseases, and at Harvard Medical School in the Department of Genetics. Where his research uncovered a long lasting impact of measles infections to erase immune memory, and showed that measles vaccines have been among the most critical public health tools to reduce overall childhood mortality.
